Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSALT Peptide for Prevention of ARDS and AKI in COVID-19
NCT04402957Phase 2Completed
- Sponsor
- Arch Biopartners
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Peptides, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of LSALT peptide in coronavirus disease 2019 (COVID-19), sponsored by Arch Biopartners. Started Oct 2020; status: completed.
02
Drugs
LSALT peptide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04402957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402957.